amphetamine has been researched along with Aggression in 113 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Aggression: Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This review examined laboratory data collected in humans, who were administered an acute dose of amphetamine or methamphetamine, in order to investigate the link between amphetamines and aggression." | 9.22 | Methamphetamine, amphetamine, and aggression in humans: A systematic review of drug administration studies. ( Casey, S; Downey, LA; Hart, CL; O'Malley, KY, 2022) |
| " Amphetamine and L-dopa pretreatment attenuated the increases in apomorphine-induced stereotypy and aggression in REMSD rats, but ECS selectively reduced apomorphine-induced aggression." | 7.67 | Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments. ( Braz, S; Ferreira, TM; Silveira Filho, NG; Troncone, LR; Tufik, S, 1988) |
| "The role of central histaminergic system in foot shock induced aggression was studied in mice." | 7.66 | Evidence for central histaminergic mechanism in foot shock aggression. ( Bhargava, KP; Dhawan, KN; Gulati, A; Gupta, GP; Nath, C, 1982) |
| " This review examined laboratory data collected in humans, who were administered an acute dose of amphetamine or methamphetamine, in order to investigate the link between amphetamines and aggression." | 5.22 | Methamphetamine, amphetamine, and aggression in humans: A systematic review of drug administration studies. ( Casey, S; Downey, LA; Hart, CL; O'Malley, KY, 2022) |
| "To review current evidence linking amphetamine use with aggression and to consider possible factors that might underlie this association." | 4.85 | Mechanisms underlying aggressive and hostile behavior in amphetamine users. ( Davis, P; Dawe, S; Lapworth, K; McKetin, R, 2009) |
| " In mice, dopamine transporter (DAT) blockade from postnatal (P) day 22 to 41 increases aggression and sensitivity to amphetamine (AMPH) behavioral stimulation in adulthood." | 4.31 | Dopamine transporter blockade during adolescence increases adult dopamine function, impulsivity, and aggression. ( Ansorge, MS; Balsam, P; Chuhma, N; Mahadevia, D; Pini, N; Rayport, S; Saha, R; Simpson, EH; Spivack, S; Stevens, GS; Suri, D; Zanni, G; Ziolkowski-Blake, A, 2023) |
| " However, the presence of PRTFDC1 in the HPRT-deficient, but not wild-type mice, increased aggression as well as sensitivity to a specific amphetamine-induced stereotypy, both of which are reminiscent of the increased aggressive and self-injurious behavior exhibited by patients with LND." | 3.77 | PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse. ( Edwards, GL; Freeman, KG; Gaval-Cruz, M; Keebaugh, AC; Mitchell, HA; Thomas, JW; Weinshenker, D, 2011) |
| " Following repeated administration of the higher dose of IMI together with AMA, we observed an increase in clonidine-induced aggression in mice, and significant enhancement of D-amphetamine-induced locomotor hyperactivity, as well as phenylephrine-induced exploratory behavior, in rats." | 3.72 | The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats. ( Dziedzicka-Wasylewska, M; Faron-Górecka, A; Rogóz, Z; Solich, J, 2004) |
| " Lack of alpha2C-AR expression was associated with increased amphetamine-induced locomotor activity, startle reactivity, aggression, and activity in the forced swimming test; prepulse inhibition of the startle reflex was attenuated." | 3.71 | Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. ( Haapalinna, A; Sallinen, J; Scheinin, M, 2001) |
| "To (1) determine the enduring nature of locomotor sensitization to alcohol; (2) examine subsequent changes to morphine and amphetamine effects on locomotor behavior; and (3) test whether behavioral sensitization to alcohol or morphine is relevant to alcohol-heightened aggression." | 3.71 | Repeated alcohol: behavioral sensitization and alcohol-heightened aggression in mice. ( DeBold, JF; Fish, EW; Miczek, KA, 2002) |
| "Mice maintained on a basal casein diet supplemented with 4% L-tyrosine potentiated L-DOPA effects on aggression." | 3.67 | Effects of drug-induced changes in brain monoamines on aggression and motor behavior in mice. ( Brown, JW; Kramarcy, NR; Thurmond, JB, 1984) |
| " The pharmacological results of the rota-rod, spontaneous motility, aggression-test, hexobarbital-potentiation and antagonism to physostigmine are reported." | 3.67 | [Synthesis and neurologic action of new 11-substituted 5H-dibenzo[b,e][1,4]diazepines]. ( Likhosherstov, AM; Rayevskii, KS; Röhnert, H; Rostock, A; Rüger, C; Skoldinov, AP; Stavrovskaja, AW, 1984) |
| " Amphetamine and L-dopa pretreatment attenuated the increases in apomorphine-induced stereotypy and aggression in REMSD rats, but ECS selectively reduced apomorphine-induced aggression." | 3.67 | Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments. ( Braz, S; Ferreira, TM; Silveira Filho, NG; Troncone, LR; Tufik, S, 1988) |
| "The role of central histaminergic system in foot shock induced aggression was studied in mice." | 3.66 | Evidence for central histaminergic mechanism in foot shock aggression. ( Bhargava, KP; Dhawan, KN; Gulati, A; Gupta, GP; Nath, C, 1982) |
| "Administration of amphetamine and methamphetamine can elicit psychiatric adverse effects at acute administration, binge use, withdrawal, and chronic use." | 2.52 | Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine. ( Harro, J, 2015) |
| "Also, a magnesium deficiency is capable of altering the potency of catecholamine stimulating drugs." | 1.27 | Magnesium deficiency alters aggressive behavior and catecholamine function. ( Kantak, KM, 1988) |
| " 4 Chronic administration of diazepam, droperidol or mescaline, all of which alter the level of aggression in different ways, can result in an inversion of the social hierarchy where a competitive rival is present in the group of mice." | 1.26 | The integrity of the social hierarchy in mice following administration of psychotropic drugs. ( Poshivalov, VP, 1980) |
| "Diazepam was equally effective, and several times more potent than chlordiazepoxide." | 1.25 | Chlordiazepoxide and diazepam induced mouse killing by rats. ( Corcia, RM; Gay, PE; Lamon, S; Leaf, RC; Wnek, DJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 85 (75.22) | 18.7374 |
| 1990's | 7 (6.19) | 18.2507 |
| 2000's | 10 (8.85) | 29.6817 |
| 2010's | 9 (7.96) | 24.3611 |
| 2020's | 2 (1.77) | 2.80 |
| Authors | Studies |
|---|---|
| O'Malley, KY | 1 |
| Hart, CL | 1 |
| Casey, S | 1 |
| Downey, LA | 1 |
| Suri, D | 1 |
| Zanni, G | 1 |
| Mahadevia, D | 2 |
| Chuhma, N | 1 |
| Saha, R | 1 |
| Spivack, S | 1 |
| Pini, N | 1 |
| Stevens, GS | 1 |
| Ziolkowski-Blake, A | 1 |
| Simpson, EH | 1 |
| Balsam, P | 1 |
| Rayport, S | 1 |
| Ansorge, MS | 2 |
| Wang, J | 1 |
| Fanous, S | 1 |
| Terwilliger, EF | 1 |
| Bass, CE | 1 |
| Hammer, RP | 1 |
| Nikulina, EM | 2 |
| Yu, Q | 1 |
| Teixeira, CM | 1 |
| Huang, Y | 1 |
| Balsam, D | 1 |
| Mann, JJ | 1 |
| Gingrich, JA | 1 |
| Heinla, I | 1 |
| Leidmaa, E | 1 |
| Visnapuu, T | 1 |
| Philips, MA | 1 |
| Vasar, E | 1 |
| Fulde, GW | 1 |
| Forster, SL | 1 |
| Harro, J | 2 |
| Kara, NZ | 1 |
| Flaisher-Grinberg, S | 1 |
| Einat, H | 1 |
| Studer, E | 1 |
| Näslund, J | 1 |
| Westman, A | 1 |
| Carlsson, A | 1 |
| Eriksson, E | 1 |
| Thorell, LB | 1 |
| Dahlström, K | 1 |
| Dawe, S | 1 |
| Davis, P | 1 |
| Lapworth, K | 1 |
| McKetin, R | 1 |
| Gobrogge, KL | 1 |
| Liu, Y | 1 |
| Young, LJ | 1 |
| Wang, Z | 1 |
| Miczek, KA | 4 |
| Takahashi, A | 1 |
| Covington, HE | 1 |
| Yap, JJ | 1 |
| Boyson, CO | 1 |
| Shimamoto, A | 1 |
| de Almeida, RM | 1 |
| Keebaugh, AC | 1 |
| Mitchell, HA | 1 |
| Gaval-Cruz, M | 1 |
| Freeman, KG | 1 |
| Edwards, GL | 1 |
| Weinshenker, D | 1 |
| Thomas, JW | 1 |
| KARLI, P | 1 |
| Dziedzicka-Wasylewska, M | 1 |
| Faron-Górecka, A | 1 |
| Rogóz, Z | 2 |
| Solich, J | 1 |
| Yang, M | 1 |
| Augustsson, H | 1 |
| Markham, CM | 1 |
| Hubbard, DT | 1 |
| Webster, D | 1 |
| Wall, PM | 1 |
| Blanchard, RJ | 1 |
| Blanchard, DC | 1 |
| Steensland, P | 1 |
| Hallberg, M | 1 |
| Kindlundh, A | 1 |
| Fahlke, C | 1 |
| Nyberg, F | 1 |
| Da Vanzo, JP | 1 |
| Daugherty, M | 1 |
| Ruckart, R | 1 |
| Kang, L | 1 |
| Romaniuk, A | 1 |
| Kramarcy, NR | 1 |
| Brown, JW | 1 |
| Thurmond, JB | 1 |
| DeBold, JF | 2 |
| Thompson, ML | 1 |
| Skoldinov, AP | 1 |
| Rayevskii, KS | 1 |
| Likhosherstov, AM | 1 |
| Stavrovskaja, AW | 1 |
| Rüger, C | 1 |
| Rostock, A | 1 |
| Röhnert, H | 1 |
| De Feo, G | 1 |
| Lisciani, R | 1 |
| Pavan, L | 1 |
| Samarelli, M | 1 |
| Valeri, P | 1 |
| Beltcheva, I | 1 |
| Stoytchev, T | 1 |
| Essman, EJ | 1 |
| Milkman, H | 2 |
| Frosch, W | 1 |
| Nath, C | 2 |
| Gulati, A | 1 |
| Dhawan, KN | 1 |
| Gupta, GP | 1 |
| Bhargava, KP | 1 |
| Sieber, B | 1 |
| Frischknecht, HR | 1 |
| Waser, PG | 1 |
| Poshivalov, VP | 2 |
| Humphries, CR | 1 |
| Paxinos, G | 1 |
| O'Brien, M | 1 |
| Steinpreis, RE | 1 |
| Sokolowski, JD | 1 |
| Papanikolaou, A | 1 |
| Salamone, JD | 1 |
| Melega, WP | 1 |
| Raleigh, MJ | 1 |
| Stout, DB | 1 |
| Huang, SC | 1 |
| Phelps, ME | 1 |
| Srivastava, SK | 1 |
| Sinha, JN | 1 |
| Sallinen, J | 2 |
| Haapalinna, A | 2 |
| Viitamaa, T | 1 |
| Kobilka, BK | 1 |
| Scheinin, M | 2 |
| Maj, J | 2 |
| Palit, G | 1 |
| Kumar, R | 1 |
| Gupta, MB | 1 |
| Saxena, RC | 1 |
| Patnaik, GK | 1 |
| Dhawan, BN | 1 |
| Millan, MJ | 1 |
| Brocco, M | 1 |
| Rivet, JM | 1 |
| Audinot, V | 1 |
| Newman-Tancredi, A | 1 |
| Maiofiss, L | 1 |
| Queriaux, S | 1 |
| Despaux, N | 1 |
| Peglion, JL | 1 |
| Dekeyne, A | 1 |
| Kask, A | 1 |
| Fish, EW | 1 |
| Coscia, L | 1 |
| Causa, P | 1 |
| Giuliani, E | 1 |
| Nunziata, A | 1 |
| Frosch, WA | 1 |
| Braestrup, C | 1 |
| Nielsen, M | 1 |
| Nielsen, EB | 1 |
| Lyon, M | 1 |
| Carlini, EA | 2 |
| Lal, H | 4 |
| Gianutsos, G | 1 |
| Puri, SK | 2 |
| Laverty, R | 1 |
| Podol'skiĭ, IIa | 1 |
| Barr, GA | 1 |
| Gibbons, JL | 1 |
| Bridger, WH | 1 |
| Wolgin, DL | 1 |
| Teitelbaum, P | 1 |
| Leaf, RC | 3 |
| Wnek, DJ | 2 |
| Lamon, S | 2 |
| Gay, PE | 2 |
| Marini, JL | 1 |
| Walters, JK | 1 |
| Sheard, MH | 2 |
| Munkvad, I | 3 |
| Allen, RP | 1 |
| Safer, D | 1 |
| Covi, L | 1 |
| Marshall, JF | 1 |
| Bovet-Nitti, F | 1 |
| Messeri, P | 1 |
| Corcia, RM | 1 |
| Sharma, R | 1 |
| Manchanda, SK | 1 |
| Nayar, U | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Nowak, G | 1 |
| Troncone, LR | 1 |
| Ferreira, TM | 1 |
| Braz, S | 1 |
| Silveira Filho, NG | 1 |
| Tufik, S | 1 |
| Winslow, JT | 1 |
| Kantak, KM | 1 |
| Valdman, AV | 1 |
| Poli, A | 1 |
| Palermo-Neto, J | 1 |
| Ferrini, R | 1 |
| Miragoli, G | 1 |
| Taccardi, B | 1 |
| Miller, RE | 1 |
| Levine, JM | 1 |
| Mirsky, IA | 1 |
| Schrold, J | 1 |
| Squires, RF | 1 |
| MacDonnell, MF | 1 |
| Fessock, L | 1 |
| Papeschi, R | 1 |
| Ferguson, J | 1 |
| Dement, W | 1 |
| Eichelman, B | 2 |
| Kostowski, W | 2 |
| Welch, BL | 2 |
| Welch, AS | 1 |
| Zetler, G | 1 |
| Otten, U | 1 |
| Dominic, JA | 1 |
| Moore, KE | 1 |
| Tinklenberg, JR | 2 |
| Woodrow, KM | 1 |
| Niemegeers, CJ | 1 |
| Van Nueten, JM | 1 |
| Janssen, PA | 1 |
| Arnold, LE | 2 |
| Wender, PH | 1 |
| McCloskey, K | 1 |
| Snyder, SH | 1 |
| Kirilcuk, V | 1 |
| Corson, SA | 1 |
| Corson, EO | 1 |
| Vergnes, M | 1 |
| Chaurand, JP | 1 |
| Henley, ED | 1 |
| Moisset, B | 1 |
| Banerjee, U | 1 |
| Geh, SL | 1 |
| Puri, S | 1 |
| Czlonkowski, A | 1 |
| van Riezen, H | 1 |
| van der Burg, WJ | 1 |
| Berendsen, H | 1 |
| Jaspar, ML | 1 |
| Murphy, PL | 1 |
| Murphy, P | 1 |
| Darley, CF | 1 |
| Roth, WT | 1 |
| Kopell, BS | 1 |
| Patni, SK | 1 |
| Dandiya, PC | 1 |
| Campbell, WE | 1 |
| Alexandris, A | 1 |
| Lundell, FW | 1 |
| Randrup, A | 2 |
| Ellinwood, EH | 1 |
| Cohen, S | 1 |
| Simon, P | 1 |
| Rubinstein, EH | 1 |
| Delgado, JM | 1 |
| Tadokoro, S | 1 |
| Gonzales, C | 1 |
| Thoa, NB | 1 |
| Ng, LK | 1 |
| Conners, CK | 1 |
| Medek, A | 1 |
| Hrbek, J | 1 |
| Navrátil, J | 1 |
| Komenda, S | 1 |
| Scott, JP | 1 |
| Lee, CT | 1 |
| Ho, JE | 1 |
| O'Brien, J | 1 |
| Kulkarni, AS | 1 |
| Sharma, VN | 1 |
| Mital, RL | 1 |
| Banerjee, SP | 1 |
| Sharma, HL | 1 |
| Valzelli, L | 1 |
| Soulairac, A | 1 |
| van Steenkiste, JN | 1 |
| van Steenkiste, J | 1 |
| DeFeo, JJ | 1 |
| Thut, P | 1 |
| Salama, AI | 1 |
| Goldberg, ME | 1 |
| Shibata, S | 1 |
| Sasakawa, S | 1 |
| Fujita, Y | 1 |
| Lapin, IP | 1 |
| Samsonova, ML | 1 |
| Milman, DH | 1 |
| Haas, H | 1 |
| Jantos, W | 1 |
| Horovitz, ZP | 1 |
| Ragozzino, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
12 reviews available for amphetamine and Aggression
| Article | Year |
|---|---|
Methamphetamine, amphetamine, and aggression in humans: A systematic review of drug administration studies.
Topics: Aggression; Amphetamine; Amphetamine-Related Disorders; Humans; Methamphetamine | 2022 |
The impact of amphetamine-type stimulants on emergency services.
Topics: Acute Disease; Aggression; Amphetamine; Amphetamine-Related Disorders; Anxiety; Central Nervous Syst | 2015 |
Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine.
Topics: Aggression; Amphetamine; Amphetamine-Related Disorders; Brain; Cognition Disorders; Humans; Mental D | 2015 |
Mechanisms underlying aggressive and hostile behavior in amphetamine users.
Topics: Aggression; Amphetamine; Disruptive, Impulse Control, and Conduct Disorders; Hostility; Humans; Para | 2009 |
Gene expression in aminergic and peptidergic cells during aggression and defeat: relevance to violence, depression and drug abuse.
Topics: Aggression; Amines; Amphetamine; Anhedonia; Animals; Brain; Brain Stem; Cocaine; Female; Gene Expres | 2011 |
Neurotransmitters systems interactions in cat brain in the control of emotional-defensive behavior.
Topics: Adrenergic Agonists; Aggression; Amphetamine; Animals; Brain; Carbachol; Cats; Dopamine; Emotions; H | 1980 |
Pharmacological, hormonal, and behavioral manipulations in analysis of aggressive behavior.
Topics: Aggression; Amphetamine; Animals; Castration; Endorphins; Ethanol; Female; Haloperidol; Hormones; Hu | 1984 |
On the roles of dopamine and noradrenaline in animal behaviour.
Topics: Adrenergic alpha-Antagonists; Aggression; Amphetamine; Animals; Apomorphine; Avoidance Learning; Beh | 1975 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
The catecholamines and aggressive behavior.
Topics: Aggression; Amphetamine; Anger; Animals; Behavior, Animal; Brain Stem; Catecholamines; Dihydroxyphen | 1973 |
Pharmacological studies on the brain mechanisms underlying two forms of behavioral excitation: stereotyped hyperactivity and "rage".
Topics: Aggression; Amphetamine; Anger; Animals; Basal Ganglia; Behavior, Animal; Brain; Brain Chemistry; Di | 1969 |
[Tranquilizing agents. Possibilities for animal studies].
Topics: Aggression; Amphetamine; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain; Conflict, | 1970 |
4 trials available for amphetamine and Aggression
| Article | Year |
|---|---|
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs.
Topics: Aggression; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; C | 1973 |
Effect of thioridazine, amphetamine and placebo on the hyperkinetic syndrome and cognitive area in mentally deficient children.
Topics: Aggression; Amphetamine; Attention; Child; Child Behavior Disorders; Clinical Trials as Topic; Human | 1968 |
Amphetamine abuse.
Topics: Acetylcholinesterase; Aggression; Amphetamine; Animals; Antisocial Personality Disorder; Behavior, A | 1971 |
97 other studies available for amphetamine and Aggression
| Article | Year |
|---|---|
Dopamine transporter blockade during adolescence increases adult dopamine function, impulsivity, and aggression.
Topics: Aggression; Amphetamine; Animals; Dopamine; Dopamine Plasma Membrane Transport Proteins; Impulsive B | 2023 |
BDNF overexpression in the ventral tegmental area prolongs social defeat stress-induced cross-sensitization to amphetamine and increases ΔFosB expression in mesocorticolimbic regions of rats.
Topics: Adenoviridae; Aggression; Amphetamine; Animals; Brain-Derived Neurotrophic Factor; Central Nervous S | 2013 |
Dopamine and serotonin signaling during two sensitive developmental periods differentially impact adult aggressive and affective behaviors in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Affect; Aggression; Amphetamine; Animals; Anxiety; Brain; Central Ne | 2014 |
Enrichment and individual housing reinforce the differences in aggressiveness and amphetamine response in 129S6/SvEv and C57BL/6 strains.
Topics: Adaptation, Psychological; Aggression; Akathisia, Drug-Induced; Amphetamine; Animals; Brain-Derived | 2014 |
Partial effects of the AMPAkine CX717 in a strain specific battery of tests for manic-like behavior in black Swiss mice.
Topics: Aggression; Amphetamine; Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Central Nerv | 2015 |
The effects of the dopamine stabilizer (-)-OSU6162 on aggressive and sexual behavior in rodents.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Dopamine Uptake Inhibitors; Exploratory Behavior | 2016 |
Children's self-reports on perceived effects on taking stimulant medication for ADHD.
Topics: Achievement; Adolescent; Aggression; Amphetamine; Attention Deficit Disorder with Hyperactivity; Att | 2009 |
Anterior hypothalamic vasopressin regulates pair-bonding and drug-induced aggression in a monogamous rodent.
Topics: Aggression; Amphetamine; Analysis of Variance; Animals; Anterior Hypothalamic Nucleus; Antidiuretic | 2009 |
PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse.
Topics: Aggression; Amphetamine; Animals; Brain; Dopamine; Fertility; Genes, Modifier; Humans; Hypoxanthine | 2011 |
[Effect of amphetamine & chlorpromazine on inter-species aggressivity between rat & mouse].
Topics: Aggression; Amphetamine; Amphetamines; Animals; Behavior; Chlorpromazine; Mice; Rats | 1958 |
The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aggression; Amantadine; Amphetamine; Ani | 2004 |
The rat exposure test: a model of mouse defensive behaviors.
Topics: Aggression; Amphetamine; Animals; Central Nervous System Stimulants; Male; Mice; Mice, Inbred BALB C | 2004 |
Amphetamine-induced aggression is enhanced in rats pre-treated with the anabolic androgenic steroid nandrolone decanoate.
Topics: Aggression; Amphetamine; Amphetamines; Animals; Behavior, Animal; Body Weight; Male; Nandrolone; Nan | 2005 |
Pharmacological and biochemical studies in isolation-induced fighting mice.
Topics: Aggression; Amitriptyline; Amphetamine; Analgesics; Animals; Anticonvulsants; Antidepressive Agents; | 1966 |
Effects of drug-induced changes in brain monoamines on aggression and motor behavior in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Aggression; Amphetamine; Animals; Biogenic Amin | 1984 |
[Synthesis and neurologic action of new 11-substituted 5H-dibenzo[b,e][1,4]diazepines].
Topics: Aggression; Amphetamine; Analgesics; Animals; Brain Chemistry; Chemical Phenomena; Chemistry; Clozap | 1984 |
Possible dopaminergic involvement in biting compulsion induced by large doses of clonidine.
Topics: Aggression; Amphetamine; Animals; Clonidine; Clozapine; Dopamine; Drug Interactions; Female; Haloper | 1983 |
Central depressive action of two N-aminomethyl derivatives of diethylpyridinedione.
Topics: Aggression; Amphetamine; Animals; Anticonvulsants; Humans; Male; Mice; Motor Activity; Pentylenetetr | 1983 |
Amphetamine alters aggressive behavior in differentially housed mice: changes in regional brain serotonin receptors.
Topics: Aggression; Amphetamine; Animals; Brain; Humans; Male; Muridae; Receptors, Serotonin | 1983 |
Theory of drug use.
Topics: Adaptation, Psychological; Adult; Aggression; Amphetamine; Anxiety; Child; Child Development; Confli | 1980 |
Evidence for central histaminergic mechanism in foot shock aggression.
Topics: Aggression; Amphetamine; Animals; Atropine; Electroshock; Female; Haloperidol; Histamine; Histamine | 1982 |
Behavioural effects of hashish in mice in comparison with other psychoactive drugs.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Cannabis; Chlorpromazine; Diazepam; Humans; Imip | 1982 |
The integrity of the social hierarchy in mice following administration of psychotropic drugs.
Topics: Aggression; Amphetamine; Animals; Diazepam; Droperidol; Hierarchy, Social; Humans; Male; Mescaline; | 1980 |
Mechanisms of PCA-induced hypothermia, ejaculation, salivation and irritability in rats.
Topics: Aggression; Amphetamine; Amphetamines; Animals; Body Temperature; Catecholamines; Drug Interactions; | 1981 |
The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat.
Topics: Aggression; Amphetamine; Animals; Clozapine; Haloperidol; Male; Phencyclidine; Rats; Rats, Sprague-D | 1994 |
Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain Chemistry; Central Nervous System Stimulan | 1997 |
Evidence for antiaggressive property of some calcium channel blockers.
Topics: Aggression; Amphetamine; Animals; Calcium Channel Blockers; Central Nervous System Stimulants; Depre | 1997 |
Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Aggression; A | 1998 |
Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems.
Topics: 5-Hydroxytryptophan; Adrenergic alpha-Agonists; Aggression; Amphetamine; Animals; Antidepressive Age | 1999 |
Quantification of behaviour in social colonies of rhesus monkey.
Topics: Aggression; Amphetamine; Animals; Central Nervous System Stimulants; Dopamine Antagonists; Feeding B | 1997 |
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multipara
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic Antagon | 2000 |
Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Central Nervous System St | 2000 |
Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models.
Topics: Acoustic Stimulation; Aggression; Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Body | 2001 |
Repeated alcohol: behavioral sensitization and alcohol-heightened aggression in mice.
Topics: Aggression; Amphetamine; Analgesics, Opioid; Animals; Behavior, Animal; Central Nervous System Depre | 2002 |
Pharmacological properties of new neuroleptic compounds.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Blood Pressure; | 1975 |
Ego functions in drug users.
Topics: Aggression; Amphetamine; Ego; Heroin Dependence; Humans; Judgment; Object Attachment; Perception; Pe | 1977 |
Benzodiazepine receptors in the brain as affected by different experimental stresses: the changes are small and not undirectional.
Topics: Aggression; Amphetamine; Animals; Benzodiazepines; Brain; Brain Chemistry; Electroshock; Female; Hum | 1979 |
Further studies of the aggressive behavior induced by delta9-tetrahydrocannabinol in REM sleep-deprived rats.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Dronabinol; Grooming; Humans; Lysergic Acid Diethylam | 1977 |
A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
Topics: Aggression; Amphetamine; Analgesics, Opioid; Animals; Apomorphine; Behavior, Animal; Brain; Cataleps | 1975 |
[Selective dopaminergic regulation of stereotyped forms of aggressive and defensive behavior].
Topics: Aggression; Amphetamine; Animals; Apomorphine; Behavior; Chinchilla; Dopamine; Humans; Levodopa; Rab | 1977 |
Inhibition of rat predatory aggression by acute and chronic D- and L-amphetamine.
Topics: Aggression; Amphetamine; Animals; Appetitive Behavior; Depression, Chemical; Dextroamphetamine; Dose | 1977 |
Role of activation and sensory stimuli in recovery from lateral hypothalamic damage in the cat.
Topics: Aggression; Amphetamine; Animals; Arousal; Behavior, Animal; Cats; Drinking Behavior; Feeding Behavi | 1978 |
Despite various drugs, cats continue to kill mice.
Topics: Aggression; Amitriptyline; Amphetamine; Animals; Avoidance Learning; Cats; Conditioning, Operant; De | 1978 |
Effects of d- and l-amphentamine on hypothalamically-elicited movement and attack in the cat.
Topics: Aggression; Amphetamine; Animals; Cats; Dextroamphetamine; Female; Humans; Hypothalamus; Male; Movem | 1979 |
The mechanism of action of psychopharmacological agents on behaviour.
Topics: Aggression; Amphetamine; Amphetamines; Animals; Behavior; Behavior, Animal; Catecholamines; Haplorhi | 1975 |
Increased orientation to sensory stimuli following medial hypothalamic damage in rats.
Topics: Aggression; Amphetamine; Animals; Brain Mapping; Feeding Behavior; Female; Humans; Hypothalamus; Mal | 1975 |
Central stimulating agents and population growth in mice.
Topics: Aggression; Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Caffeine; Environment, Control | 1975 |
Chlordiazepoxide and diazepam induced mouse killing by rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Chlordiazepoxide; Diazepam; Dose-Response Relati | 1975 |
Role of opioid receptors in self-aggression in rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Male; Naloxone; Norepinephrine; Pain; Phenoxyben | 1991 |
Pharmacological properties of EXP 561, a potential antidepressant drug.
Topics: Aggression; Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Blood Pressu | 1987 |
Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Bromocriptine; Carbidopa; Dopamine; Imipramine; Levod | 1988 |
Naltrexone blocks amphetamine-induced hyperactivity, but not disruption of social and agonistic behavior in mice and squirrel monkeys.
Topics: Aggression; Agonistic Behavior; Amphetamine; Animals; Female; Male; Mice; Motor Activity; Naltrexone | 1988 |
Magnesium deficiency alters aggressive behavior and catecholamine function.
Topics: Aggression; Agonistic Behavior; Amphetamine; Animals; Apomorphine; Body Weight; Catecholamines; Fema | 1988 |
Pharmaco-ethological analysis of antidepressant drug effects.
Topics: Aggression; Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Fluoxetine; Imipramine; I | 1986 |
Effects of d,1-propranolol and haloperidol on aggressive behavior induced in mice by isolation and isolation plus amphetamine treatment.
Topics: Aggression; Agonistic Behavior; Amphetamine; Animals; Haloperidol; Mice; Propranolol; Social Isolati | 1986 |
Neuro-pharmacological studies on SB 5833, a new psychotherapeutic agent of the benzodiazepine class.
Topics: Aggression; Amphetamine; Animals; Anti-Anxiety Agents; Avoidance Learning; Carbamates; Chlordiazepox | 1974 |
Effects of psychoactive drugs on nonverbal communication and group social behavior of monkeys.
Topics: Aggression; Amphetamine; Animals; Avoidance Learning; Behavior, Animal; Chlorpromazine; Conditioning | 1973 |
Behavioural effects of d-amphetamine in young chicks treated with p-Cl-phenylalanine.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain Chemistry; Chickens; Esters; Fenclonine; H | 1971 |
Some effects of ethanol, amphetamine, disulfiram and p-CPA on seizing of prey in feline predatory attack and on associated motor pathways.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Cats; Disulfiram; Electric Stimulation; Ethanol; | 1972 |
An investigation on the behavioral and hypothermic effects of yohimbine: interaction with drugs affecting central and peripheral monoamines.
Topics: 5-Hydroxytryptophan; Aggression; Amphetamine; Animals; Apomorphine; Atropine; Behavior, Animal; Bens | 1974 |
Aggressive behavior: Modification by amphetamine, p-chlorophenylalanine and lithium in rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain Stem; Female; Fenclonine; Humans; Lithium; | 1973 |
The behavioral effects of amphetamine on REM deprived rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Female; Humans; Male; Rats; Sexual Behavior, Ani | 1969 |
A note on the effects of some psychotropic drugs on the aggressive behaviour in the ant, Formica rufa.
Topics: Aggression; Amphetamine; Animals; Ants; Behavior, Animal; Chlordiazepoxide; Chlorpromazine; Humans; | 1966 |
Stimulus-dependent antagonism of the alpha-methyltyrosine-induced lowering of brain catecholamines by (+)-amphetamine in intact mice.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain Chemistry; Catecholamines; Dopamine; Drug | 1967 |
[Aggressiveness of the rat following combined treatment with monomaime oxidase inhibitors and other psychotropic drugs, especially thymoleptics].
Topics: Aggression; Alkaloids; Amitriptyline; Amphetamine; Animals; Anthracenes; Body Temperature; Central N | 1969 |
Behavior and brain contents of catecholamines in mice during chronic administration of methyldopa.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain; Catecholamines; Dopamine; Drug Tolerance; | 1971 |
Drug use among youthful assaultive and sexual offenders.
Topics: Adolescent; Adult; Aggression; Alcoholism; Amphetamine; Barbiturates; California; Cannabis; Cocaine; | 1974 |
Azaperone, a sedative neuroleptic of the butyrophenone series with pronounced anti-aggressive and anti-shock activity in animals.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Body Temperature Regulation; Butyrophenones; Dog | 1974 |
[Amphetaminic activation, hippocampal theta rhythm and rat-mouse interspecific aggression behavior].
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, D | 1972 |
Catecholamine uptake in cerebral cortex: adaptive change induced by fighting.
Topics: Age Factors; Aggression; Amphetamine; Animals; Behavior, Animal; Cerebral Cortex; Humans; In Vitro T | 1973 |
Time-related interaction patterns of amphetamine with reserpine and other central depressants.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Chlorpromazine; Diazepam; Drug Synergism; Ethano | 1973 |
Effect of dopaminergic stimulation or blockade on morphine-withdrawal aggression.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Dihydroxyphenylalanine; Haloperidol; Humans; Male; Me | 1973 |
The activity of some neuroleptic drugs and amphetamine in normal and isolated rats.
Topics: Aggression; Amphetamine; Animals; Brain; Catalepsy; Chlorpromazine; Dopamine; Haloperidol; Humans; M | 1973 |
OI 77, a new tricyclic antidepressant.
Topics: Aggression; Amphetamine; Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Cats; Drug Sy | 1973 |
Drug involvement in criminal assaults by adolescents.
Topics: Adolescent; Aggression; Alcoholic Intoxication; Amphetamine; Barbiturates; California; Cannabis; Coc | 1974 |
Apomorphine induced biting and fighting behaviour in reserpinized rats and an approach to the mechanism of action.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Chlorpromazine; Clonid | 1974 |
Canine hyperkinesis.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Dogs; Humans; Hyperkinesis; Male | 1974 |
Inhibition induced by forebrain stimulation in the monkey.
Topics: Aggression; Amphetamine; Amygdala; Animals; Autonomic Nervous System; Avoidance Learning; Behavior, | 1963 |
[Effect of drugs on socially induced suppression in monkeys].
Topics: Aggression; Amphetamine; Animals; Female; Haplorhini; Humans; Male; Morphine; Pentobarbital; Reinfor | 1967 |
Aggressive behaviour induced by marihuana compounds and amphetamine in rats previously made dependent on morphine.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Cannabis; Food Deprivation; Humans; Morphine Dep | 1972 |
Shock-induced aggression: effects of 6-hydroxydopamine and other pharmacological agents.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Brain; Catecholamines; Desipramine; Dihydroxyphenylal | 1972 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
The effect of chlorprothixene and caffeine on the conditioned alimentary motor reflexes in cats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Caffeine; Cats; Chlorprothixene; Conditioning, C | 1971 |
Effects of fighting, genotype, and amphetamine sulfate on body temperature of mice.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Body Temperature; Fever; Genetics, Behavioral; G | 1971 |
Morphine-withdrawal aggression: sensitization by amphetamines.
Topics: Aggression; Amphetamine; Animals; Dextroamphetamine; Humans; Hydroxylamines; Male; Methylphenidate; | 1971 |
DOPA and other naturally occurring substances as causes of stereotypy and rage in rats.
Topics: 5-Hydroxytryptophan; Aggression; Amphetamine; Animals; Behavior, Animal; Dihydroxyphenylalanine; Hum | 1966 |
Muricidal block produced by 5-hydroxytryptophan and various drugs.
Topics: 5-Hydroxytryptophan; Aggression; Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Desi | 1968 |
Pharmacological studies with some newly synthesized phenothiazines exhibiting lesser extrapyramidal reactions.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Catalepsy; Central Nervous System; Chemical Phen | 1969 |
The exploratory behaviour in normal and aggressive mice.
Topics: Aggression; Amphetamine; Animals; Chlordiazepoxide; Chlorpromazine; Desipramine; Exploratory Behavio | 1969 |
[Influence of atropine treatment (with or without chronic psychologic aggression) on immunization in Wistar rats].
Topics: Aggression; Amphetamine; Animals; Atropine; Chlorpromazine; Humans; Immunization; Neostigmine; Rats | 1969 |
Prevention of pain-induced aggression by parachloroamphetamine.
Topics: Aggression; Amphetamine; Animals; Chlorine; Humans; Injections, Intraperitoneal; Male; Pain; Rats | 1970 |
Neurochemical effects of imipramine and amphetamine in aggressive mouse-killing (muricidal) rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Brain; Brain Chemistry; Humans; Imipramine; Kine | 1970 |
The central depressant profile of carbamate ester of glycerol ether: 3-(1,2,3,4-tetrahydro-7-naphthyloxy)-2-hydroxypropyl carbamate.
Topics: Aggression; Amphetamine; Animals; Anticonvulsants; Blood Pressure; Carbamates; Cats; Chemical Phenom | 1967 |
[Species differences in the effects of apomorphine as an adrenergic agent].
Topics: Aggression; Amphetamine; Animals; Apomorphine; Body Temperature; Chinchilla; Female; Humans; Male; M | 1968 |
The role of maribuana in patterns of drug abuse by adolescents.
Topics: Adolescent; Adult; Aggression; Amphetamine; Barbiturates; Cannabis; Catatonia; Chronic Disease; Diss | 1969 |
[Modification of central mechanisms of action by anticholinergics].
Topics: Aggression; Amphetamine; Animals; Apomorphine; Atropine; Biperiden; Bridged-Ring Compounds; Central | 1969 |
Selective block of rat mouse-killing by antidepressants.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Chlordiazepoxide; Chlorpromazine; Humans; Imipra | 1965 |